BC Week In Review | Nov 10, 2017
Company News

Huahai gets license to Eutilex's EU-101

Eutilex Co. Ltd. (Seoul, South Korea) granted Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) exclusive rights to develop and commercialize preclinical cancer candidate EU-101 in Taiwan and China, including Hong Kong and Macau. Eutilex received a...
BC Extra | Nov 6, 2017
Company News

Huahai gets license to Eutilex's EU-101

Eutilex Co. Ltd. (Seoul, South Korea) granted Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) exclusive rights to develop and commercialize preclinical cancer candidate EU-101 in Taiwan and China, including Hong Kong and Macau. Eutilex received a...
BC Extra | Dec 9, 2016
Financial News

T cell play Eutilex raises W21B in series A

Immuno-oncology company Eutilex Co. Ltd. (Seoul, South Korea) raised W21 billion ($18.9 million) in a series A round from DS Asset Management, Kolon Investment, G.N. Tech Venture and SNU Bio Angel. Eutilex said the money...
Items per page:
1 - 3 of 3